Astrazeneca PLC ASTRAZENECA ADR REPRESENTING 0.5 ORD SHS
Astrazeneca PLC ASTRAZENECA ADR R.../ US0463531089 /
0A4J
21/05/2024 14:40:24
|
Chg.
-
|
Volume |
Bid06:00:08 |
Ask06:00:08 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
77.60USD
|
-
|
24,812 Turnover: 1.35 mill. |
-Bid Size: - |
-Ask Size: - |
265.18 bill.USD |
- |
22.32 |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Company calendar
CW 37 | 09/09/2024
Dividend Payment
|
CW 46 | 12/11/2024
Interim Report 3rd Quarter/9 Months
|